期刊文献+

胃癌组织中表皮生长因子受体和环氧合酶-2的表达及其临床意义 被引量:1

Expression of epidermal growth factor receptor and cyclooxygenase-2 in gastric carcinoma tissues and their clinical significance
下载PDF
导出
摘要 目的探讨表皮生长因子受体(epithelial growth factor receptor,EGFR)和环氧合酶-2(cyclooxygenase-2,COX-2)在胃癌组织中的表达及其临床意义与相互关系。方法采用免疫组化Envision二步法检测40例胃癌组织中EGFR和COX-2的表达。结果 IEGFR表达阳性率为72.50%(29/40),COX-2阳性表达率为52.50%(21/40),二者的表达与胃癌淋巴结转移明显相关(P<0.05);②EGFR和COX-2在胃癌中的阳性表达与临床分期有关,在TNM分期中Ⅲ+Ⅳ期阳性表达率高于Ⅰ+Ⅱ期(P<0.05);③胃癌组织中COX-2表达与EGFR表达之间存在相关性(P<0.05)。结论 COX-2和EGFR过度表达参与了胃癌的发生发展过程,并与其淋巴结转移和TNM分期有关;胃癌中COX-2和EGFR的表达具有正向协同性。 To investigate the expression of epidermal growth factor receptor(EGFR)and cyclooxygenase(COX)-2 in gastric carcinoma tissues and their clinical significance and correlation. The Envision immunohistochemical two-step method was used to detect the expression of EGFR and COX-2 in 40 cases of gastric carcinoma tissues. The positive expression rate of EGFR was 72.50%(29/40),and that of COX-2 was 52.50%(21/40).The expression of EGFR and COX-2 was significant correlated with lymph node metastasis in gastric carcinoma(P 0.05).The positive expression of EGFR and COX-2 in gastric carcinoma was correlated with its clinical stage.The positive expression of EGFR and COX-2 in patients in stage Ⅲ+Ⅳ was higher than that in stage I+II(P 0.05).The expression of EGFR was closely correlated with that of COX-2(P 0.05). The overexpression of COX-2 and EGFR participates in the pathogenesis of gastric carcinoma,and is correlated with lymph node metastasis and the clinical stage of gastric carcinoma.Positive cooperativity can be seen in the expression of EGFR and COX-2 in gastric carcinoma.
出处 《实用医院临床杂志》 2012年第2期68-70,共3页 Practical Journal of Clinical Medicine
关键词 胃癌 表皮生长因子受体 环氧合酶-2 免疫组织化学 Gastric carcinoma Epidermal growth factor receptor Cyclooxygenase-2 Immunohistochemistry
  • 相关文献

参考文献3

二级参考文献54

  • 1郑敏,Simon R,Kononen J,Sauter G,Mihatsch MJ,Moch H.使用cDNA微阵列和组织微阵列对三种上皮性卵巢肿瘤基因表达的分析[J].癌症,2004,23(7):771-776. 被引量:8
  • 2Cheng-BoHan,Xiao-YunMao,YanXin,Shao-ChengWang,Jia-MingMa,Yu-JieZhao.Quantitative analysis of tumor mitochondrial RNA using microarray[J].World Journal of Gastroenterology,2005,11(1):36-40. 被引量:4
  • 3Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001; 7:987-989
  • 4Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10:145-147
  • 5Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E. Phase Ⅱ, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21:60-65
  • 6Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342
  • 7Kopetz S, Glover KY, Eng C, Wolff RA, Chang DZ, Adinin RB, Morris J, Abbruzzese JL, Hoff PM. Phase Ⅱ study of infusional, 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) plus bevacizumab as first line treaterment for metastatic colorectal cancer. J Clin Oncol(Meeting Abstracts) 2007; 25: 18S Abst 4089
  • 8Sobrero AF, Young S, Belcewicz M, Young S, Balcewicz M, Chiarra S, Perez Carrion R, Mainwaring P, Gapski J, Clarke S, Langer B, Ackland S. Phase Ⅳ study of first line bevacizumab plus irinotecan and infusional 5-FU/LV in patients with metastatic colorectal cancer: AVIRI. J Clin Oncol(Meeting Abstracts) 2007; 25: 18S Abst 4068
  • 9Grothey A, Sugrue M, Hedrick E, D. Purdie D, Yi J,Dong W, Kozloff M. Association between exposure to bevacizumab (BV) beyond first progression (BBP) and overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Results from a large observational study (BRITE). J Clin Oncol(Meeting Abstracts) 2007; 25: 18S Abst 4036
  • 10Kretzschmer A, Van Cutsem E, Micheal M, Rivera F, Berry S, DiBartolomeo M, Mazier M, Lutiger B, Cunningham D. Preliminary efficacy of bevacizumab with first-line FOLFOX, XELOX, FOLFIRI and monotherapy for mCRC: First BEA Trial. J Clin Oncol(Meeting Abstracts) 2007; 25: 18S Abst 4072

共引文献66

同被引文献11

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部